Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
NOT_YET_RECRUITING
Clinical Phase
EARLY_PHASE1
Total Enrollment
60 participants
Study Classification
INTERVENTIONAL
Study Start Date
2025-01-01
Study Completion Date
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Based on the scientific evidence, the relevance of this subject, we consider this study to be justified, the general or specific objective of which is as follows:
'To evaluate the effect of the administration of Osteoimplant© and Osteoimplant Complex© as a food supplement in obtaining implant stability and in the healing of dental implant surgery'.
As secondary objectives, we will also evaluate the effect of Osteoimplant© and Osteoimplant Complex© on pain, postoperative inflammation and soft tissue healing.
The sample will consist of 60 patients. The sample will be randomly divided into 2 groups using a randomisation table generated by a statistical programme. For blinding, neither the patient nor the operator shall be aware of the group to which each patient belongs. To ensure blinding, medication will be delivered in sealed, opaque envelopes. Patients shall be assigned to one of the following groups:
* Group I: 30 patients prescribed to take Osteoimplant Complex© on the following schedule: 2 tablets per day starting 5 days before implant placement and 1 tablet per day of Osteimplant© for 2 months after implant placement.
* Group II: 30 patients who were prescribed placebo with the following regimen: 2 tablets per day starting 5 days before implant placement and 1 tablet per day for 2 months after implant placement.
'To evaluate the effect of the administration of Osteoimplant© and Osteoimplant Complex© as a food supplement in obtaining implant stability and in the healing of dental implant surgery'.
As secondary objectives, we will also evaluate the effect of Osteoimplant© and Osteoimplant Complex© on pain, postoperative inflammation and soft tissue healing.
The sample will consist of 60 patients. The sample will be randomly divided into 2 groups using a randomisation table generated by a statistical programme. For blinding, neither the patient nor the operator shall be aware of the group to which each patient belongs. To ensure blinding, medication will be delivered in sealed, opaque envelopes. Patients shall be assigned to one of the following groups:
* Group I: 30 patients prescribed to take Osteoimplant Complex© on the following schedule: 2 tablets per day starting 5 days before implant placement and 1 tablet per day of Osteimplant© for 2 months after implant placement.
* Group II: 30 patients who were prescribed placebo with the following regimen: 2 tablets per day starting 5 days before implant placement and 1 tablet per day for 2 months after implant placement.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Osteoimplant and Bone Healing
NCT06664060
Dimensional Changes
Bone Density
NOT_YET_RECRUITING
EARLY_PHASE1
Implant/Abutment Module Stability of Original vs Compatible Connections
NCT03524872
Bone Loss, Alveolar
Dental Implant Failure Nos
UNKNOWN
NA
Patient-reported Outcomes and Esthetics With Single Dental Implants
NCT06571201
Patient Reported Outcome Measures
Patient Satisfaction
Implant Complication
COMPLETED
A Triple-blinded Non-inferiority Multicentre Randomized Controlled Trial Comparing Hybrid and Fully Etched Implants P1
NCT06100120
Dental Implants
RECRUITING
NA
Immediate Placement and Stabilization of Dental Implants With Tetranite Stabilization Material in Mandibular and Maxillary Tooth Extraction Sites That Fail to Provide Adequate Primary Stability
NCT04121364
Adhesive Dental
COMPLETED
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Based on the scientific evidence, the relevance of this subject, we consider this study to be justified, the general or specific objective of which is as follows:
'To evaluate the effect of the administration of Osteoimplant© and Osteoimplant Complex© as a food supplement in obtaining implant stability and in the healing of dental implant surgery'.
As secondary objectives, we will also evaluate the effect of Osteoimplant© and Osteoimplant Complex© on pain, postoperative inflammation and soft tissue healing.
The sample will consist of 60 patients. The sample will be randomly divided into 2 groups using a randomisation table generated by a statistical programme. For blinding, neither the patient nor the operator shall be aware of the group to which each patient belongs. To ensure blinding, medication will be delivered in sealed, opaque envelopes. Patients shall be assigned to one of the following groups:
* Group I: 30 patients prescribed to take Osteoimplant Complex© on the following schedule: 2 tablets per day starting 5 days before implant placement and 1 tablet per day of Osteimplant© for 2 months after implant placement.
* Group II: 30 patients who were prescribed placebo with the following regimen: 2 tablets per day starting 5 days before implant placement and 1 tablet per day for 2 months after implant placement.
3.1. Study design Our study is a double-blind randomised clinical trial (RCT) to evaluate the stability of the implants in the different phases of treatment: at the time of insertion (primary stability), at 8 and 12 weeks (secondary stability). Postoperative pain and swelling will also be studied.
Composition of nutritional supplements.
* The preoperative nutritional supplement corresponds to Osteoimplant Complex® and is composed of: vitamin C 48.5 mg, coenzyme Q10 41.3 mg, Zinc 35 mg, beta-carotene 10% 25 mg, bioflavonoids citrus 60% 20.83 mg, vitamin E and magnesium 15 mg.
* The post-operative nutritional supplement corresponds to Osteoimplant®, and is composed of: Ovocet ®, collagen 350 mg, calcium 300 mg, vitamin D3 100IU/mg, magnesium 8 mg.
Patients Conceptual or target population Patients with partial or total single tooth edentulism requiring rehabilitation with intraosseous implants.
Study or accessible population The patients who will form part of our study will be those who attend the Master's Degree in Oral Surgery and Implantology of the Faculty of Dentistry of the University of Granada requesting dental implants for their rehabilitation.
All patients will undergo a clinical history and subsequent clinical examination. The clinical history will consist of an anamnesis, where the patient's personal details will be collected (name, age, sex, profession, address and telephone number), as well as family history, illnesses suffered, previous surgical interventions, drug allergies and current treatment. Subsequently, an intraoral and extraoral examination will be carried out, consisting of inspection and palpation of the bucco-facial territory.
To complement our examination and make a correct diagnosis, all patients will undergo a radiological study as a step prior to surgery, which will always consist of an orthopantomography, the usual projection for this type of intervention, with which a correct diagnosis can be made. In addition, we will complete the study with a CBCT in order to assess three-dimensionally the relationship with anatomical structures and the availability of bone.
Once the diagnosis has been correctly made, the patient will be informed, both orally and in writing, of the possible complications that may arise in this type of surgery. The following inclusion and exclusion criteria will be applied to the target population for participation in the study:
Inclusion criteria:
* Patients presenting with unitary or partial edentulism.
* Age: Between 18-75 years.
* Anaesthetic risk ASA I-II.
* Patients who do not abuse alcohol, drugs or chronic smoking (\>10 cigarettes/day).
* Patients with adequate periodontal status (≤10% plaque index and bleeding index).
* Absence of drug allergies that could compromise our study.
* Absence of allergy to any of the components of Osteoimplant© and Osteimplant Complex©.
* Signed informed consent.
Exclusion criteria:
* Age not between 18-75 years old.
* Pregnant or breastfeeding women.
* Chronic smokers (\>10 cigarettes/day).
* Patients with decompensated metabolic disease.
* Poor periodontal status (≥10% plaque index and bleeding index).
* Patients allergic to any of the components of Osteoimplant© and Osteimplant Complex©.
* Patients undergoing treatment with drugs that could affect the bone regeneration process, such as chemotherapy drugs, bisphosphonates, corticosteroids or immunosuppressants.
* Patients with metabolic bone diseases or who have undergone radiotherapy in the last five years.
* Patients with hypercalcaemia or a tendency to hypercalcification, taking vitamin D or calcium supplements.
* Patients with a history of renal colic.
* Patients who are not going to undergo nephrotic colic. 1. Surgical Protocol First of all, the patient rinses with 0.12% chlorhexidine. After 1 minute, the area to be implanted is anaesthetised using a truncal block or infiltrative technique with 4% articaine together with epinephrine. A transcrestal or paracrestal incision is made, depending on the case, and the mucoperiosteal flap is detached. Once detached, the position of the implant will be determined thanks to the in situ visualisation of the bone thickness and the previous CBCT study of each patient. Subsequently, the drilling sequence is determined by the company itself. Once the implant bed has been created, we will proceed to insert the implant with a torque of at least 30-45N. At this point, the first stability measurement will be taken, then the cover screw will be placed and the flap and suture will be repositioned. The patient will be reviewed and given a series of postoperative guidelines in physical format, which it is essential to follow for a correct result of our surgery.
All implants will be placed following the same surgical protocol and in strict compliance with the implant manufacturer's instructions regarding the drilling protocol associated with the patient's bone quality.
Once the implants are placed, stability measurements shall be taken with the Osstell ISQ and the stability levels of the implants shall be evaluated at different stages of treatment by performing the following measurements:
1. First measurement: after implant placement surgery. We will evaluate the primary stability.
2. Second measurement: at 8 weeks to determine the evolution of osseointegration throughout the healing process of our implants.
3. Third measurement: at 12 weeks to assess the evolution of osseointegration again before subjecting the implant to occlusal loads.
Prior to implant placement, each patient will be assigned to a study group, where, depending on their assignment, they will receive either placebo or the drug in question:
Preoperative phase:
* Group I: prescribed to take Osteoimplant Complex ® 2 every 24 hours, 5 days prior to surgery.
* Group II: prescribed to take placebo 2 every 24 hours, 5 days prior to surgery.
Post-operative phase:
* Group I: prescribed to take Osteoimplant® 1 every 24 hours, for 8 weeks after surgery.
* Group II: prescribed placebo 1 every 24 hours for 8 weeks after surgery. In both groups, an antibiotic treatment of amoxicillin 500 mg, 1 every 8 hours for 5 days is administered. In case of penicillin allergy, the drug of choice will be clindamycin 300 mg 1 every 8 hours for 5 days; as well as an analgesic and anti-inflammatory treatment: ibuprofen 400 mg 1 every 8 hours for 2 days, from the third day on demand. As rescue medication paracetamol 1 g.
'To evaluate the effect of the administration of Osteoimplant© and Osteoimplant Complex© as a food supplement in obtaining implant stability and in the healing of dental implant surgery'.
As secondary objectives, we will also evaluate the effect of Osteoimplant© and Osteoimplant Complex© on pain, postoperative inflammation and soft tissue healing.
The sample will consist of 60 patients. The sample will be randomly divided into 2 groups using a randomisation table generated by a statistical programme. For blinding, neither the patient nor the operator shall be aware of the group to which each patient belongs. To ensure blinding, medication will be delivered in sealed, opaque envelopes. Patients shall be assigned to one of the following groups:
* Group I: 30 patients prescribed to take Osteoimplant Complex© on the following schedule: 2 tablets per day starting 5 days before implant placement and 1 tablet per day of Osteimplant© for 2 months after implant placement.
* Group II: 30 patients who were prescribed placebo with the following regimen: 2 tablets per day starting 5 days before implant placement and 1 tablet per day for 2 months after implant placement.
3.1. Study design Our study is a double-blind randomised clinical trial (RCT) to evaluate the stability of the implants in the different phases of treatment: at the time of insertion (primary stability), at 8 and 12 weeks (secondary stability). Postoperative pain and swelling will also be studied.
Composition of nutritional supplements.
* The preoperative nutritional supplement corresponds to Osteoimplant Complex® and is composed of: vitamin C 48.5 mg, coenzyme Q10 41.3 mg, Zinc 35 mg, beta-carotene 10% 25 mg, bioflavonoids citrus 60% 20.83 mg, vitamin E and magnesium 15 mg.
* The post-operative nutritional supplement corresponds to Osteoimplant®, and is composed of: Ovocet ®, collagen 350 mg, calcium 300 mg, vitamin D3 100IU/mg, magnesium 8 mg.
Patients Conceptual or target population Patients with partial or total single tooth edentulism requiring rehabilitation with intraosseous implants.
Study or accessible population The patients who will form part of our study will be those who attend the Master's Degree in Oral Surgery and Implantology of the Faculty of Dentistry of the University of Granada requesting dental implants for their rehabilitation.
All patients will undergo a clinical history and subsequent clinical examination. The clinical history will consist of an anamnesis, where the patient's personal details will be collected (name, age, sex, profession, address and telephone number), as well as family history, illnesses suffered, previous surgical interventions, drug allergies and current treatment. Subsequently, an intraoral and extraoral examination will be carried out, consisting of inspection and palpation of the bucco-facial territory.
To complement our examination and make a correct diagnosis, all patients will undergo a radiological study as a step prior to surgery, which will always consist of an orthopantomography, the usual projection for this type of intervention, with which a correct diagnosis can be made. In addition, we will complete the study with a CBCT in order to assess three-dimensionally the relationship with anatomical structures and the availability of bone.
Once the diagnosis has been correctly made, the patient will be informed, both orally and in writing, of the possible complications that may arise in this type of surgery. The following inclusion and exclusion criteria will be applied to the target population for participation in the study:
Inclusion criteria:
* Patients presenting with unitary or partial edentulism.
* Age: Between 18-75 years.
* Anaesthetic risk ASA I-II.
* Patients who do not abuse alcohol, drugs or chronic smoking (\>10 cigarettes/day).
* Patients with adequate periodontal status (≤10% plaque index and bleeding index).
* Absence of drug allergies that could compromise our study.
* Absence of allergy to any of the components of Osteoimplant© and Osteimplant Complex©.
* Signed informed consent.
Exclusion criteria:
* Age not between 18-75 years old.
* Pregnant or breastfeeding women.
* Chronic smokers (\>10 cigarettes/day).
* Patients with decompensated metabolic disease.
* Poor periodontal status (≥10% plaque index and bleeding index).
* Patients allergic to any of the components of Osteoimplant© and Osteimplant Complex©.
* Patients undergoing treatment with drugs that could affect the bone regeneration process, such as chemotherapy drugs, bisphosphonates, corticosteroids or immunosuppressants.
* Patients with metabolic bone diseases or who have undergone radiotherapy in the last five years.
* Patients with hypercalcaemia or a tendency to hypercalcification, taking vitamin D or calcium supplements.
* Patients with a history of renal colic.
* Patients who are not going to undergo nephrotic colic. 1. Surgical Protocol First of all, the patient rinses with 0.12% chlorhexidine. After 1 minute, the area to be implanted is anaesthetised using a truncal block or infiltrative technique with 4% articaine together with epinephrine. A transcrestal or paracrestal incision is made, depending on the case, and the mucoperiosteal flap is detached. Once detached, the position of the implant will be determined thanks to the in situ visualisation of the bone thickness and the previous CBCT study of each patient. Subsequently, the drilling sequence is determined by the company itself. Once the implant bed has been created, we will proceed to insert the implant with a torque of at least 30-45N. At this point, the first stability measurement will be taken, then the cover screw will be placed and the flap and suture will be repositioned. The patient will be reviewed and given a series of postoperative guidelines in physical format, which it is essential to follow for a correct result of our surgery.
All implants will be placed following the same surgical protocol and in strict compliance with the implant manufacturer's instructions regarding the drilling protocol associated with the patient's bone quality.
Once the implants are placed, stability measurements shall be taken with the Osstell ISQ and the stability levels of the implants shall be evaluated at different stages of treatment by performing the following measurements:
1. First measurement: after implant placement surgery. We will evaluate the primary stability.
2. Second measurement: at 8 weeks to determine the evolution of osseointegration throughout the healing process of our implants.
3. Third measurement: at 12 weeks to assess the evolution of osseointegration again before subjecting the implant to occlusal loads.
Prior to implant placement, each patient will be assigned to a study group, where, depending on their assignment, they will receive either placebo or the drug in question:
Preoperative phase:
* Group I: prescribed to take Osteoimplant Complex ® 2 every 24 hours, 5 days prior to surgery.
* Group II: prescribed to take placebo 2 every 24 hours, 5 days prior to surgery.
Post-operative phase:
* Group I: prescribed to take Osteoimplant® 1 every 24 hours, for 8 weeks after surgery.
* Group II: prescribed placebo 1 every 24 hours for 8 weeks after surgery. In both groups, an antibiotic treatment of amoxicillin 500 mg, 1 every 8 hours for 5 days is administered. In case of penicillin allergy, the drug of choice will be clindamycin 300 mg 1 every 8 hours for 5 days; as well as an analgesic and anti-inflammatory treatment: ibuprofen 400 mg 1 every 8 hours for 2 days, from the third day on demand. As rescue medication paracetamol 1 g.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Primary Stability of the Implants
Pain
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
TRIPLE
Participants
Investigators
Outcome Assessors
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
OSTEOIMPLANT GROUP
patients prescribed to take Osteoimplant Complex© on the following schedule: 2 tablets per day starting 5 days before implant placement and 1 tablet per day of Osteimplant© for 2 months after implant placement.
Group Type
EXPERIMENTAL
osteoimplant
Intervention Type
DIETARY_SUPPLEMENT
Osteoimplant Complex© on the following schedule: 2 tablets per day starting 5 days before implant placement and 1 tablet per day of Osteimplant© for 2 months after implant placement.
Placebo Group
30 patients who were prescribed placebo with the following regimen: 2 tablets per day starting 5 days before implant placement and 1 tablet per day for 2 months after implant placement.
Group Type
PLACEBO_COMPARATOR
Placebo Oral Tablet
Intervention Type
DIETARY_SUPPLEMENT
2 tablets per day starting 5 days before implant placement and 1 tablet per day for 2 months after implant placement.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
osteoimplant
Osteoimplant Complex© on the following schedule: 2 tablets per day starting 5 days before implant placement and 1 tablet per day of Osteimplant© for 2 months after implant placement.
Intervention Type
DIETARY_SUPPLEMENT
Placebo Oral Tablet
2 tablets per day starting 5 days before implant placement and 1 tablet per day for 2 months after implant placement.
Intervention Type
DIETARY_SUPPLEMENT
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients presenting with unitary or partial edentulism.
* Age: Between 18-75 years.
* Anaesthetic risk ASA I-II.
* Patients who do not abuse alcohol, drugs or chronic smoking (\>10 cigarettes/day).
* Patients with adequate periodontal status (≤10% plaque index and bleeding index).
* Absence of drug allergies that could compromise our study.
* Absence of allergy to any of the components of Osteoimplant© and Osteimplant Complex©.
* Signed informed consent.
* Age: Between 18-75 years.
* Anaesthetic risk ASA I-II.
* Patients who do not abuse alcohol, drugs or chronic smoking (\>10 cigarettes/day).
* Patients with adequate periodontal status (≤10% plaque index and bleeding index).
* Absence of drug allergies that could compromise our study.
* Absence of allergy to any of the components of Osteoimplant© and Osteimplant Complex©.
* Signed informed consent.
Exclusion Criteria
* Age not between 18-75 years old.
* Pregnant or breastfeeding women.
* Chronic smokers (\>10 cigarettes/day).
* Patients with decompensated metabolic disease.
* Poor periodontal status (≥10% plaque index and bleeding index).
* Patients allergic to any of the components of Osteoimplant© and Osteimplant Complex©.
* Patients undergoing treatment with drugs that could affect the bone regeneration process, such as chemotherapy drugs, bisphosphonates, corticosteroids or immunosuppressants.
* Patients with metabolic bone diseases or who have undergone radiotherapy in the last five years.
* Patients with hypercalcaemia or a tendency to hypercalcification, taking vitamin D or calcium supplements.
* Patients with a history of renal colic.
* Patients who are not going to undergo nephrotic colic.
* Pregnant or breastfeeding women.
* Chronic smokers (\>10 cigarettes/day).
* Patients with decompensated metabolic disease.
* Poor periodontal status (≥10% plaque index and bleeding index).
* Patients allergic to any of the components of Osteoimplant© and Osteimplant Complex©.
* Patients undergoing treatment with drugs that could affect the bone regeneration process, such as chemotherapy drugs, bisphosphonates, corticosteroids or immunosuppressants.
* Patients with metabolic bone diseases or who have undergone radiotherapy in the last five years.
* Patients with hypercalcaemia or a tendency to hypercalcification, taking vitamin D or calcium supplements.
* Patients with a history of renal colic.
* Patients who are not going to undergo nephrotic colic.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Universidad de Granada
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Francisco Javier Manzano-Moreno
PhD, Doctor in Dental Surgery
Responsibility Role
PRINCIPAL_INVESTIGATOR
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
FRANCISCO JAVIER MANZANO-MORENO Prof. Dr. Francisco Javier Manzano-Moreno, PhD, DDS
Role: CONTACT
+34651606228
References
Explore related publications, articles, or registry entries linked to this study.
Chen MH, Lyons KM, Tawse-Smith A, Ma S. Clinical Significance of the Use of Resonance Frequency Analysis in Assessing Implant Stability: A Systematic Review. Int J Prosthodont. 2019 Jan/Feb;32(1):51-58. doi: 10.11607/ijp.6048.
Reference Type
RESULT
Werny JG, Sagheb K, Diaz L, Kammerer PW, Al-Nawas B, Schiegnitz E. Does vitamin D have an effect on osseointegration of dental implants? A systematic review. Int J Implant Dent. 2022 Apr 11;8(1):16. doi: 10.1186/s40729-022-00414-6.
Reference Type
RESULT
Dermience M, Lognay G, Mathieu F, Goyens P. Effects of thirty elements on bone metabolism. J Trace Elem Med Biol. 2015 Oct;32:86-106. doi: 10.1016/j.jtemb.2015.06.005. Epub 2015 Jun 26.
Reference Type
RESULT
Choi HK, Kim GJ, Yoo HS, Song DH, Chung KH, Lee KJ, Koo YT, An JH. Vitamin C Activates Osteoblastogenesis and Inhibits Osteoclastogenesis via Wnt/beta-Catenin/ATF4 Signaling Pathways. Nutrients. 2019 Feb 27;11(3):506. doi: 10.3390/nu11030506.
Reference Type
RESULT
Kim JH, Lim YJ, Kim B, Lee J. How Do Parameters of Implant Primary Stability Correspond with CT-Evaluated Bone Quality in the Posterior Maxilla? A Correlation Analysis. Materials (Basel). 2021 Jan 7;14(2):270. doi: 10.3390/ma14020270.
Reference Type
RESULT
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
4054/CEIH/2024
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Primary Stability and Peri-implant Outcomes of Short Implants in Post-extraction Single-tooth Sites
NCT07177521
RECRUITING
NA
Surgical Treatment of Peri-implantitis With and Without an Initial Non-surgical Approach
NCT03620331
COMPLETED
NA
Combined Tooth-implant Supported Prostheses
NCT05712031
COMPLETED
NA
Photobiomodulation and Implant Stability
NCT04495335
UNKNOWN
NA
Dental Implants Rehabilitation in Patients With Vitamin D3 Imbalance
NCT04841213
COMPLETED
NA
Effect of Placing the Implant Crown on the Implant on the Same Day as the Implant vs. 4 Weeks Later.
NCT04319042
RECRUITING
NA
Randomized Clinical Trial to Evaluate the Predictability of 5.5 mm Dental Implants
NCT04929743
COMPLETED
NA
Osseodensification and Dental Implant Stability
NCT05376020
UNKNOWN
NA
Bone Level Tapered Multi-Center Study
NCT02569671
ACTIVE_NOT_RECRUITING
NA
Effect of Xenogeneic Collagen Matrix on the Peri-implant Tissues of Immediate Implants.
NCT04980313
UNKNOWN
NA
Implants Immediately Installed in Esthetic Area With Computer-guided Surgery
NCT03986164
COMPLETED
NA
Implant Insertion Torque and Primary Stability
NCT03222219
COMPLETED
Clinical Efficacy of the Immediate Implant Loading
NCT03305679
COMPLETED
NA
Esthetic Outcomes of Immediately Placed Implants Receiving Immediate Provisionalization and Delayed Restoration
NCT01925339
COMPLETED
NA
Comparative Study of Immediate Single Unit Implants in Early Loading Protocols, With or Without Photobiomodulation.
NCT05106855
COMPLETED
NA
Surface Topography and Color Stability of Conventional, 3D Printed, and Milled Provisional Restorations.
NCT06946693
RECRUITING
NA
Evaluation of Osseointegration Process of Dental Implants
NCT06099834
COMPLETED
NA
Effect of Undersized Drilling Upon the Immediate Implants
NCT04345133
COMPLETED
NA
Primary and Secondary Stability of a One-Piece Compressive Implant System
NCT06800508
RECRUITING
Clinical and Microbiological Outcomes of Dental Implants After 10-22 Years of Function
NCT06803576
ENROLLING_BY_INVITATION
Clinical Influence of Different Surface Treatments on Implant Stabiity
NCT06808724
RECRUITING
Influence of Gum Disease Treatment on Long-term Dental Implant Success
NCT03841656
UNKNOWN
Accuracy of Static Guided Implant Surgery: 3D-printed vs Milled Surgical Guides
NCT06819995
RECRUITING
NA
Evaluation of Immediate Versus Delayed Loading of Dental Implants With a Modified Surface
NCT00782171
COMPLETED
PHASE4